Wagner Farid Gattaz

List of Publications by Year
in descending order

150	6,885	53794 45	69250 77
papers	citations	h-index	g-index

165	165	165	8695
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: An updated systematic review and meta-analysis. World Journal of Biological Psychiatry, 2023, 24, 24-33.	2.6	10
2	COX-2 pathway is upregulated in ultra-high risk individuals for psychosis. World Journal of Biological Psychiatry, 2022, 23, 236-241.	2.6	2
3	Antipsychotics preserve telomere length in peripheral blood mononuclear cells after acute oxidative stress injury. Neural Regeneration Research, 2022, 17, 1156.	3.0	3
4	Exacerbation of psychosis risk during the COVID-19 pandemic: The disproportionate impact on the lower income population. Psychiatry Research, 2022, 307, 114319.	3.3	11
5	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. Journal of Affective Disorders, 2022, 308, 71-75.	4.1	4
6	Decision tree-based classification as a support to diagnosis in the Alzheimer's disease continuum using cerebrospinal fluid biomarkers: insights from automated analysis. Revista Brasileira De Psiquiatria, 2022, , .	1.7	0
7	Prefrontal resting-state connectivity and antidepressant response: no associations in the ELECT-TDCS trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 123-134.	3.2	4
8	Increased PLA2 activity in individuals at ultra-high risk for psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1593-1599.	3.2	2
9	Genetic polymorphisms of the serotonin transporter are not related with depression in temporal lobe epilepsy caused by hippocampal sclerosis. Epilepsy and Behavior, 2021, 117, 107854.	1.7	0
10	Influence of migration on the thought process of individuals at ultra-high risk for psychosis. Revista Brasileira De Psiquiatria, 2021, 43, 285-288.	1.7	3
11	Translation and validation of the Structured Interview for Prodromal Syndromes (SIPS) to Portuguese. Revista Brasileira De Psiquiatria, 2021, 43, 560-562.	1.7	5
12	Cognitive Patterns and Conversion in a Representative Sample of Individuals at Risk for Psychosis. Journal of Nervous and Mental Disease, 2021, Publish Ahead of Print, .	1.0	2
13	Use of a Bayesian Network Model to predict psychiatric illness in individuals with â€˜at risk mental statesâ€™ from a general population cohort. Neuroscience Letters, 2021, 770, 136358.	2.1	0
14	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimerâ€™s disease: a pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 483-488.	3.2	10
15	Reduced Annexin A3 in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 489-494.	3.2	9
16	Cognitive changes after tDCS and escitalopram treatment in major depressive disorder: Results from the placebo-controlled ELECT-TDCS trial. Journal of Affective Disorders, 2020, 263, 344-352.	4.1	13
17	Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2063-2072.	2.2	0
18	Childhood maltreatment in individuals at risk of psychosis: Results from the Brazilian SSAPP cohort. International Journal of Social Psychiatry, 2020, 66, 566-575.	3.1	3

#	Article	IF	Citations
19	Addressing Mood Disorder Diagnosis' Stigma With an Honest, Open, Proud (HOP)-Based Intervention: A Randomized Controlled Trial. Frontiers in Psychiatry, 2020, 11, 582180.	2.6	5
20	Precision non-implantable neuromodulation therapies: a perspective for the depressed brain. Revista Brasileira De Psiquiatria, 2020, 42, 403-419.	1.7	19
21	Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimerâ€™s disease patients. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 963-972.	3.2	27
22	Schizophrenia TreAtment with electRic Transcranial Stimulation (STARTS): design, rationale and objectives of a randomized, double-blinded, sham-controlled trial. Trends in Psychiatry and Psychotherapy, 2019, 41, 104-111.	0.8	5
23	Antidepressant effects of tDCS are associated with prefrontal gray matter volumes at baseline: Evidence from the ELECT-TDCS trial. Brain Stimulation, 2019, 12, 1197-1204.	1.6	33
24	Disclosing the diagnosis of schizophrenia: A pilot study of the â€˜Coming Out Proudâ€™ intervention. International Journal of Social Psychiatry, 2019, 65, 244-251.	3.1	8
25	Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. British Journal of Psychiatry, 2019, 215, 668-674.	2.8	91
26	Plasma metabolites in first episode psychoses. Schizophrenia Research, 2019, 206, 468-470.	2.0	6
27	Higher transcription alleles of the MAOA-uVNTR polymorphism are associated with higher seizure frequency in temporal lobe epilepsy. Epilepsy Research, 2019, 149, 26-29.	1.6	5
28	Hearing spirits? Religiosity in individuals at risk for psychosisâ€"Results from the Brazilian SSAPP cohort. Schizophrenia Research, 2019, 204, 353-359.	2.0	20
29	Plasma lipids metabolism in mild cognitive impairment and Alzheimerâ€™s disease. World Journal of Biological Psychiatry, 2019, 20, 190-196.	2.6	18
30	Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimerâ€™s disease patients. Revista De Psiquiatria Clinica, 2019, 46, 120-124.	0.6	15
31	Cognitive outcomes of TMS treatment in bipolar depression: Safety data from a randomized controlled trial. Journal of Affective Disorders, 2018, 235, 20-26.	4.1	44
32	Chronic Lithium Treatment Increases Telomere Length in Parietal Cortex and Hippocampus of Triple-Transgenic Alzheimerâ€™s Disease Mice. Journal of Alzheimer's Disease, 2018, 63, 93-101.	2.6	20
33	Glycogen synthase kinase-3Î² activity and cognitive functioning in patients with bipolar I disorder. European Neuropsychopharmacology, 2018, 28, 361-368.	0.7	4
34	Kynurenine is correlated with IL-1Î² in plasma of schizophrenia patients. Journal of Neural Transmission, 2018, 125, 869-873.	2.8	18
35	Genetic polymorphisms of the 5HT receptors are not related with depression in temporal lobe epilepsy caused by hippocampal sclerosis. Epilepsy and Behavior, 2018, 83, 181-185.	1.7	6
36	Increased platelet glycogen sysnthase kinase 3beta in first-episode psychosis. Schizophrenia Research, 2018, 195, 402-405.	2.0	4

#	Article	IF	Citations
37	Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimerâ€™s disease patients. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 501-507.	3.2	13
38	BDNF Val66Met polymorphism is not related with temporal lobe epilepsy caused by hippocampal sclerosis in Brazilian population. Seizure: the Journal of the British Epilepsy Association, 2018, 60, 159-162.	2.0	6
39	Treatment of Bipolar Depression with Deep TMS: Results from a Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial. Neuropsychopharmacology, 2017, 42, 2593-2601.	5.4	69
40	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia â€“ a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	2.4	61
41	The schizophrenia stigma and mass media: a search for news published by wide circulation media in Brazil. International Review of Psychiatry, 2017, 29, 241-247.	2.8	13
42	Network Meta-analysis in Mental Health Researchâ€”Reply. JAMA Psychiatry, 2017, 74, 851.	11.0	1
43	Poverty, low education, and the expression of psychotic-like experiences in the general population of SÃ£o Paulo, Brazil. Psychiatry Research, 2017, 253, 182-188.	3.3	35
44	Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes. JAMA Psychiatry, 2017, 74, 143.	11.0	355
45	Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. New England Journal of Medicine, 2017, 376, 2523-2533.	27.0	284
46	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	1.9	119
47	Stereological investigation of the CA1 pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. Annals of Anatomy, 2017, 209, 51-60.	1.9	14
48	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	2.6	33
49	Glycogen synthase kinaseâ€3Î² in patients with bipolar I disorder: results from a prospective study. Bipolar Disorders, 2016, 18, 334-341.	1.9	8
50	Mental healthcare in South America with a focus on Brazil. Current Opinion in Psychiatry, 2016, 29, 264-269.	6.3	17
51	Glycogen Synthase Kinase-3Î²: Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. Neuropsychobiology, 2016, 73, 108-115.	1.9	5
52	Cognitive impairment in lateâ€life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Bipolar Disorders, 2016, 18, 63-70.	1.9	32
53	Longâ€term lithium treatment increases intracellular and extracellular brainâ€derived neurotrophic factor (<scp>BDNF</scp>) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar Disorders, 2016, 18, 692-695.	1.9	33
54	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. NeuroImage: Clinical, 2016, 12, 1-15.	2.7	107

#	Article	IF	Citations
55	Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 607-618.	3.2	8
56	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. Schizophrenia Research, 2016, 177, 67-69.	2.0	11
57	Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial. PLoS ONE, 2016, 11, e0154195.	2.5	40
58	Lithium Distinctly Modulates the Secretion of Pro- and Anti- Inflammatory Interleukins in Co-Cultures of Neurons and Glial Cells at Therapeutic and Sub-Therapeutic Concentrations. Current Alzheimer Research, 2016, 13, 848-852.	1.4	19
59	Home-Based Psychiatric Outpatient Care Through Videoconferencing for Depression: A Randomized Controlled Follow-Up Trial. JMIR Mental Health, 2016, 3, e36.	3.3	34
60	Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons. Molecules, 2015, 20, 19878-19885.	3.8	14
61	Epistasis between COMT Val158Met and DRD3 Ser9Gly polymorphisms and cognitive function in schizophrenia: genetic influence on dopamine transmission. Revista Brasileira De Psiquiatria, 2015, 37, 235-241.	1.7	11
62	Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. European Neuropsychopharmacology, 2015, 25, 468-473.	0.7	65
63	Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects. Journal of Alzheimer's Disease, 2015, 46, 423-429.	2.6	71
64	Hippocampal serotonin depletion is related to the presence of generalized tonicâ€“clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy. Epilepsy Research, 2015, 111, 18-25.	1.6	18
65	Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial. Journal of Affective Disorders, 2015, 185, 209-213.	4.1	24
66	Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue. Journal of Neural Transmission, 2015, 122, 1371-1380.	2.8	22
67	Lithium increases platelet serine-9 phosphorylated GSK-3Î² levels in drug-free bipolar disorder during depressive episodes. Journal of Psychiatric Research, 2015, 62, 78-83.	3.1	47
68	Bimodal Effect of Lithium Plasma Levels on Hippocampal Glutamate Concentrations in Bipolar II Depression: A Pilot Study. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	18
69	A Longitudinal (6-week) 3T 1H-MRS Study on the Effects of Lithium Treatment on Anterior Cingulate Cortex Metabolites in Bipolar Depression. European Neuropsychopharmacology, 2015, 25, 2311-2317.	0.7	50
70	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 455-463.	2.4	77
71	Regulation of leukocyte tricarboxylic acid cycle in drug-naÃ¯ve Bipolar Disorder. Neuroscience Letters, 2015, 605, 65-68.	2.1	12
72	Chronic inhibition of brain phospholipase A2 in adult rats impairs the survival of newborn mature neurons in the hippocampus. Journal of Neural Transmission, 2015, 122, 619-628.	2.8	3

#	Article	IF	Citations
73	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 91-96.	4.8	32
74	Reduced activities of phospholipases A₂ in platelets of drugâ€naÃ¯ve bipolar disorder patients. Bipolar Disorders, 2015, 17, 97-101.	1.9	10
75	Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 243-246.	4.8	27
76	Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 167-170.	3.2	10
77	The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects. PLoS ONE, 2015, 10, e0136141.	2.5	11
78	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: A systematic review and meta-analysis. World Journal of Biological Psychiatry, 2014, 15, 411-418.	2.6	89
79	Reduced Cerebrospinal Fluid Levels of Brain-Derived Neurotrophic Factor Is Associated With Cognitive Impairment in Late-Life Major Depression. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2014, 69, 845-851.	3.9	54
80	Patterns of stigma toward schizophrenia among the general population: A latent profile analysis. International Journal of Social Psychiatry, 2014, 60, 595-605.	3.1	17
81	Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus. Journal of Neural Transmission, 2014, 121, 695-706.	2.8	4
82	Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimerâ€™s disease: a 4-year follow-up study. Journal of Neural Transmission, 2014, 121, 193-200.	2.8	26
83	Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. Journal of Psychiatric Research, 2014, 50, 36-41.	3.1	135
84	Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. Journal of Psychiatric Research, 2014, 55, 96-100.	3.1	24
85	Long-Term Lithium Treatment Reduces Glucose Metabolism in the Cerebellum and Hippocampus of Nondemented Older Adults: An [¹⁸F]FDG-PET Study. ACS Chemical Neuroscience, 2014, 5, 484-489.	3.5	19
86	Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clinical and Translational Allergy, 2014, 4, P49.	3.2	0
87	Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clinical and Translational Allergy, 2014, 4, P118.	3.2	0
88	BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: Results from a factorial, randomized, sham-controlled trial. European Neuropsychopharmacology, 2014, 24, 1144-1151.	0.7	42
89	Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Current Medical Research and Opinion, 2014, 30, 695-709.	1.9	6
90	Leukocyte telomerase activity and antidepressant efficacy in bipolar disorder. European Neuropsychopharmacology, 2014, 24, 1139-1143.	0.7	16

#	Article	IF	Citations
91	Lithium Decreases Plasma Adiponectin Levels in Bipolar Depression. Neuroscience Letters, 2014, 564, 111-114.	2.1	34
92	Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study. Experimental and Therapeutic Medicine, 2014, 8, 1205-1208.	1.8	19
93	Long-Term, Low-Dose Lithium Treatment Does Not Impair Renal Function in the Elderly. Journal of Clinical Psychiatry, 2014, 75, e672-e678.	2.2	67
94	Stigma toward schizophrenia: do all psychiatrists behave the same? Latent profile analysis of a national sample of psychiatrists in Brazil. BMC Psychiatry, 2013, 13, 92.	2.6	33
95	The more information, the more negative stigma towards schizophrenia: Brazilian general population and psychiatrists compared. Psychiatry Research, 2013, 205, 185-191.	3.3	41
96	Correlation between platelet and brain PLA2 activity. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 265-268.	2.2	7
97	Antipsychotic drugs decrease iPLA 2 gene expression in schizophrenia. Schizophrenia Research, 2013, 147, 203-204.	2.0	7
98	A radioenzymatic assay to identify three groups of phospholipase A2 in platelets. Prostaglandins Leukotrienes and Essential Fatty Acids, 2012, 86, 149-153.	2.2	10
99	Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. Journal of Psychiatric Research, 2012, 46, 1053-1058.	3.1	20
100	Does Lithium Prevent AlzheimerÊ¼s Disease?. Drugs and Aging, 2012, 29, 335-342.	2.7	122
101	Inhibition of cPLA₂and sPLA₂Activities in Primary Cultures of Rat Cortical Neurons byCentella asiaticaWater Extract. Natural Product Communications, 2012, 7, 1934578X1200700.	0.5	9
102	Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. Neuroscience Letters, 2011, 494, 54-56.	2.1	125
103	Inhibition of phospholipase A2 in rat brain modifies different membrane fluidity parameters in opposite ways. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1612-1617.	4.8	21
104	Higher Serum sTNFR1 Level Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1305-1311.	2.6	85
105	Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimerâ€™s disease. Journal of Psychiatric Research, 2011, 45, 220-224.	3.1	88
106	Increased PLA2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis. Journal of Psychiatric Research, 2011, 45, 1617-1620.	3.1	20
107	Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein. Journal of Neural Transmission, 2011, 118, 1273-1279.	2.8	22
108	Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 351-356.	2.8	319

#	Article	IF	Citations
109	Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment?. World Journal of Biological Psychiatry, 2011, 12, 216-222.	2.6	42
110	Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. Journal of Psychiatric Research, 2010, 44, 917-920.	3.1	49
111	Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Medicine, 2010, 8, 89.	5.5	95
112	Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Revista Brasileira De Psiquiatria, 2010, 32, 216-222.	1.7	49
113	Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World Journal of Biological Psychiatry, 2010, 11, 550-555.	2.6	56
114	Inhibition of phospholipase A2 increases Tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukotrienes and Essential Fatty Acids, 2010, 82, 57-60.	2.2	15
115	Differential roles of phospholipases A2 in neuronal death and neurogenesis: Implications for Alzheimer disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1381-1389.	4.8	29
116	Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry, 2010, 11, 110-120.	2.6	82
117	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. Journal of Psychiatric Research, 2009, 43, 978-986.	3.1	165
118	Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. Journal of Neural Transmission, 2009, 116, 275-289.	2.8	137
119	Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 16-22.	3.2	93
120	Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 151-163.	3.2	180
121	Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology, 2009, 202, 37-51.	3.1	60
122	Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry, 2009, 9, 17.	2.6	133
123	Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: Preliminary evidence. Psychiatry Research, 2009, 165, 1-9.	3.3	61
124	Increased Serum IL-1Î² Level in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 28, 507-512.	1.5	177
125	Diagnostic transitions in mild cognitive impairment subtypes. International Psychogeriatrics, 2009, 21, 1088-1095.	1.0	86
126	Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology, 2008, 198, 1-27.	3.1	82

#	Article	IF	Citations
127	Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukotrienes and Essential Fatty Acids, 2008, 78, 265-269.	2.2	25
128	Language impairment in euthymic, elderly patients with bipolar disorder but no dementia. International Psychogeriatrics, 2008, 20, 687-696.	1.0	23
129	Mild cognitive impairment: cognitive screening or neuropsychological assessment?. Revista Brasileira De Psiquiatria, 2008, 30, 316-321.	1.7	63
130	Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. British Journal of Psychiatry, 2007, 190, 359-360.	2.8	323
131	Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukotrienes and Essential Fatty Acids, 2007, 76, 47-55.	2.2	38
132	Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 340-343.	3.2	30
133	Reduced phospholipid breakdown in Alzheimerâ€™s brains: a 31P spectroscopy study. Psychopharmacology, 2005, 180, 359-365.	3.1	45
134	Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology, 2005, 181, 392-400.	3.1	53
135	Childhood meningitis increases the risk for adult schizophrenia. World Journal of Biological Psychiatry, 2005, 6, 44-48.	2.6	43
136	Childhood meningitis, brain maturation and the risk of psychosis*. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 23-26.	3.2	52
137	Inhibition of platelet phospholipase A2 activity by catuaba extract suggests antiin?ammatory properties. Phytotherapy Research, 2004, 18, 942-944.	5.8	25
138	Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biological Psychiatry, 2004, 56, 41-45.	1.3	111
139	Rightward cerebral asymmetry in subtypes of schizophrenia according to Leonhard's classification and to DSM-IV: a structural MRI study. Psychiatry Research - Neuroimaging, 2003, 123, 65-79.	1.8	23
140	Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophrenia Research, 2003, 61, 1-6.	2.0	104
141	P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism. Schizophrenia Research, 2002, 58, 117-122.	2.0	43
142	Lack of association between schizophrenia and the phospholipase-A2 genes cPLA2 and sPLA2. American Journal of Medical Genetics Part A, 2001, 105, 246-249.	2.4	38
143	Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophrenia Research, 2000, 43, 91-95.	2.0	57
144	Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 55, 109-113.	2.2	44

#	Article	IF	Citations
145	Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: Possible implications for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1995, 246, 13-16.	3.2	13
146	Decreased phospholipase A2 activity in Alzheimer brains. Biological Psychiatry, 1995, 37, 13-17.	1.3	100
147	Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. Psychiatry Research, 1995, 58, 165-169.	3.3	7
148	Phospholipase A2 in Schizophrenia. Biological Psychiatry, 1992, 31, 214-216.	1.3	10
149	Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biological Psychiatry, 1991, 30, 837-840.	1.3	58
150	Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry, 1987, 22, 421-426.	1.3	208